Keros Therapeutics (KROS) Return on Sales (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Return on Sales came in at 1.25% in Q4 2025, down 110.0% YoY from 12.48% in Q4 2024, and down 24111.13% on a QoQ basis from 0.01% in Q3 2025.
Keros Therapeutics (KROS) Return on Sales (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Return on Sales data on file, last reported at 1.25% in Q4 2025.
- Quarterly Return on Sales fell 110.0% year-over-year to 1.25% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0% (up 54.0% YoY) and the FY2025 annual result came in at 0.0%, up 53.0% from the prior year.
- Return on Sales fell to 1.25% in Q4 2025, from 0.01% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.01% in Q1 2025 to a low of 96.1% in Q3 2023.
- A 5-year average of 7.31% and a median of 0.15% in 2024 frame the typical range for Return on Sales.
- Annual changes were most pronounced in 2023 — Return on Sales tumbled 9608 bps — and 2024, when it jumped 9474 bps.
- Tracing KROS's Return on Sales over 5 years: stood at 0.0% in 2021, then tumbled by 1400 bps to 0.06% in 2022, then slumped by 5380 bps to 3.19% in 2023, then soared by 95 bps to 0.15% in 2024, then plunged by 725 bps to 1.25% in 2025.
- The last three Return on Sales figures came in at 1.25% (Q4 2025), 0.01% (Q3 2025), and 0.02% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | 0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.01% |
| Dec 31, 2025 | -1.25% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.02% |
| Mar 31, 2025 | 0.01% |
| Dec 31, 2024 | -0.15% |
| Sep 30, 2024 | -1.36% |
| Jun 30, 2024 | -9.01% |
| Mar 31, 2024 | -5.19% |
| Dec 31, 2023 | -3.19% |
| Sep 30, 2023 | -96.10% |
| Dec 31, 2022 | -0.06% |
| Sep 30, 2022 | -0.02% |
| Jun 30, 2022 | -0.02% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | -6.25% |
| Jun 30, 2021 | -1.56% |
| Sep 30, 2020 | -0.15% |
| Jun 30, 2020 | -0.06% |